Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial

Reuters

2025/11/03

<a href="https://laohu8.com/S/IOVA">Iovance Biotherapeutics</a> Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial

Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte $(TIL)$ cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566984-en) on November 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580975872"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580975872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580975872?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580975872","market":"fut","top_or_hot":-1,"title":"Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566984-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-03 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566984-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLWS0rT:1","article_id":"2580975872","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580975872","pubTimestamp":1762171240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte  cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer  without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IOVA":"Iovance Biotherapeutics, Inc.","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4139":"生物科技"},"translate_title":"Iovance Biotherapeutics报告Lifileucel在晚期非小细胞肺癌试验中的缓解率为26%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IOVA":0.9},"content_text":"Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial\n    \n\n        Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte $(TIL)$ cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566984-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}